Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

A Phase 1 Study of THR 687: An Integrin Antagonist for the Treatment of Diabetic Macular Edema (DME)

 

Arshad M. Khanani, MD, MA

A Phase 1 Study of THR 687: An Integrin Antagonist for the Treatment of Diabetic Macular Edema (DME)

February 8, 2020

Publication date: 
February, 2020